CYTO (Altamira Therapeutics) Earnings per share growth rate in current year
The absence of commercial products and rising R&D costs drive current dynamics, resulting in the annual earnings per share growth metric stalling at 64.80. This is driven by Altamira Therapeutics (CYTO) pursuing leadership in RNA therapy via peptide cell delivery. Scaling potential is based on strategic alliances and the integration of the Peptide+ IT platform into partner formulas.
Comprehensive metric breakdowns and analytics for altamiratherapeutics.com (CYTO)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
Debt to Equity Altamira Therapeutics|CYTO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Altamira Therapeutics Ltd.|CYTO - Company Aggregate Debts|Debts to Book Capitalization Altamira Therapeutics|CYTO - Company Long-Term Debt|Company Current Liabilities Altamira Therapeutics|Interim Coverage Ratio altamiratherapeutics.com
- net income and valuation multiples indicators:
CYTO - Company Net Income|Expected Net Income Altamira Therapeutics|CYTO - P/E Multiple|Forward P/E Multiple Altamira Therapeutics Ltd.|CYTO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Altamira Therapeutics|CYTO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Altamira Therapeutics|CYTO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months altamiratherapeutics.com|CYTO - Earnings growth in current year|Expected net earnings per share growth next year Altamira Therapeutics
- sales volume and revenue information:
Fundamental valuation:Altamira Therapeutics
This metric measures the dynamics of net earnings per share, reflecting the rate of capital recovery relative to the previous year. Analyzing year-over-year EPS growth percentages allows for the differentiation of sustainable business strengthening from random volatile spikes. For Altamira Therapeutics (CYTO), such a metric is critical, as it confirms the effectiveness of monetizing patent-protected nanotechnologies amidst costly clinical trials.
Main competitors
Haleon PLC - Earnings per share increase in current year|KVUE (Kenvue Corp) - Earnings growth in current year|Earnings per share growth rate in current year Verona Pharma Inc. VRNA|Earnings per share growth in current year Jyong Biotech Ltd (MENS)|LGND (ligand.com) - Earnings per share increase in current year|Earnings growth in current year AMRX (Amneal)|Earnings growth in current year Perrigo Company PLC PRGO|ALVO - Earnings per share growth in current year|LQDA: Earnings per share growth in current year|GLPG (Galapagos NV) - Net earnings per share growth this year|ANIP: Net earnings per one share growth for the current year|MNKD (MannKind) - Earnings growth in current year|Earnings growth in current year Amphastar Pharmaceuticals Inc|Earnings per share growth in current year Pacira (PCRX)|Net earnings per share growth this year ARS Corp SPRY|Earnings growth in current year TBPH (Theravance Biopharma)|Expected net earnings per share growth this year aquestive.com (AQST)|SCPH - Earnings per share growth in current year|Earnings per share increase in current year TECX (Tectonic Therapeutic, Inc.)|TNXP: Earnings growth in current year|China SXT Pharmaceuticals, Inc. (SXTC) - Earnings growth in current year|Net earnings per share growth this year EPRX|BHST: Earnings per share increase in current year|Net earnings per share growth this year EXOZ (eXoZymes)|Net earnings per one share growth for the current year ORMP|Earnings growth in current year ENTX (Entera Bio)|Earnings per share increase in current year HYFT|ABVC BioPharma - Earnings growth in current year|Earnings per share growth rate in current year cumberlandpharma.com|Quantum BioPharma (QNTM) - Earnings per share growth in current year|FibroGen Inc - Earnings per share increase in current year|TELO (Telomir Pharma) - Earnings growth in current year|Earnings growth in current year Rani Therapeutics Inc|Earnings per share growth in current year Synergy CHC Corp (SNYR)|RLYB: Earnings per share trend in current year|Earnings growth in current year LEXX (Lexaria Bioscience Corp.)|Pulmatrix Inc (PULM) - Earnings per share growth rate in current year|PTHL: Net earnings per share growth this year|APM - Earnings growth in current year|LYRA (Lyra Therapeutics, Inc.) - Net earnings per share growth this year|IBO: Net earnings per one share growth for the current year|TNFA (TNF Pharmaceuticals Inc.) - Earnings growth in current year|cbdMD Corp (YCBD) - Expected net earnings per share growth this year|Earnings growth in current year PRFX|Net earnings per share growth this year Lipella Pharma LIPO|Earnings per share growth in current year OptiNose, Inc. OPTN|Expected net earnings per share growth this year pieris.com (PIRS)|Procaps - Earnings growth in current year|Petros Pharmaceuticals Inc (PTPI) - Net earnings per share growth this year|QLI (Qilian International Holding Group Limited) - Net earnings per share growth this year|Earnings per share growth rate in current year ACELYRIN Inc. (SLRN)|Net earnings per share growth this year TFFP
